title: Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer.
abstract: BACKGROUND
  The aim of this study was to assess the efficacy and safety of vinorelbine and cisplatin (NP chemotherapy) alone or in combination with Aidi injection for the treatment of advanced nonsmall cell lung cancer (NSCLC).
  
  
  METHODS
  Pertinent publications were identified in PubMed, EMBASE, Cochrane Library, CNKI, CQVIP, and Wanfang databases, up to December 8, 2015. After quality assessment of all included randomized controlled trials evaluating Aidi injection combined with NP chemotherapy for the treatment of advanced NSCLC, a meta-analysis was performed by Review Manager 5.2 and STATA 12.0 for statistical analyses.
  
  
  RESULTS
  Twelve studies including 509 and 503 cases in the experimental and control groups, respectively, were finally analyzed. The meta-analysis revealed that when cisplatin dose ranging from 20 to 40 mg/m 2 , combination of Aidi injection and NP chemotherapy was statistically different compared with NP chemotherapy alone in enhancing efficiency (relative risk [RR] = 1.24, 95% confidence interval [CI] [1.05-1.47], P = 0.010) and reducing the incidence of Grade II or above nausea and vomiting (RR = 0.49, 95% CI [0.30-0.80], P = 0.005). Meanwhile, with cisplatin ranging from 80 to 120 mg/m 2 , no significant differences in efficiency (RR = 1.11, 95% CI [0.87-1.42], P = 0.390) and Grade II or above nausea and vomiting (RR = 0.88, 95% CI [0.71-1.10], P = 0.260) were obtained. In addition, Aidi injection combined with NP chemotherapy was superior to NP chemotherapy alone in improving the quality of life, alleviating Grade II or above leukopenia and thrombocytopenia.
  
  
  CONCLUSIONS
  Aidi injection combined with NP chemotherapy can enhance efficiency, improve the quality of life, and decrease adverse effects in patients with advanced NSCLC.
authors.forename: Hua-Ye
authors.initials: HY
authors.lastname: Zhao
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Zhou
authors.forename: Yan-Ting
authors.initials: YT
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Shu-Ya
authors.initials: SY
authors.lastname: Qi
authors.forename: Jun-Ling
authors.initials: JL
authors.lastname: Cao
authors.affiliation: Department of Pharmacy, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Guo-Hui
authors.initials: GH
authors.lastname: Li
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000523:psychology; D002945:Cisplatin / Q000008:administration & dosage; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000523:psychology; D017594:Publication Bias; D011788:Quality of Life; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D004365:Drugs, Chinese Herbal; C517300:aidi herbal drug; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine